reports
Koninklijke BAM Group N.V.: 1 director
A director at Koninklijke BAM Group N.V. sold 74,204 shares at 4.200EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Sean Conroy
OSE Immunotherapeutics - Full Lusvertikimab results reflect potential ...
OSE Immunotherapeutics’ final analysis of the CoTikiS trial in ulcerative colitis (UC) confirmed that Lusvertikimab met the primary endpoint with statistical significance, highlighting its potential to offer a clinically meaningful solution for the condition. In our view, this marks a positive step forward for the candidate, which, to our knowledge, has a unique mechanism of action to address chronic inflammatory and autoimmune diseases. We believe that OSE plans to advance this programme to the...
Solutions30 announces Thomas Kremer as new Supervisory Board Chair and...
Solutions30 announces Thomas Kremer as new Supervisory Board Chair and Pascale Mourvillier as new Audit, Risk and Compliance Committee Chair Solutions30, a European leader in rapid-response field services for the telecommunications, energy and IT sectors, today announces significant changes to the leadership of its Supervisory Board and Audit, Risk and Compliance Committee, reflecting the Group’s ongoing commitment to strong corporate governance and strategic oversight. Thomas Kremer appointed Chair of the Supervisory Board Thomas Kremer has been appointed as Chair of the Supervisory Boar...
Solutions30 annonce la nomination de Thomas Kremer comme nouveau Prési...
Solutions30 annonce la nomination de Thomas Kremer comme nouveau Président du Conseil de Surveillance et de Pascale Mourvillier comme nouvelle Présidente du Comité Audit, Risque et Conformité Solutions30, leader européen des services de terrain à intervention rapide pour les secteurs des télécommunications, de l’énergie et de l’informatique, annonce aujourd’hui des changements majeurs à la présidence de son Conseil de Surveillance et de son Comité Audit, Risque et Conformité, témoignant de l’engagement continu du Groupe en faveur d’une gouvernance d’entreprise solide et d’un pilotage straté...
Guerbet annonce le lancement commercial en France d’Elucirem® (Gadopic...
Guerbet annonce le lancement commercial en France d’Elucirem® (Gadopiclenol) son nouveau produit de contraste pour les examens d’imagerie par résonance magnétique (IRM). Guerbet annonce le lancement commercial en France d’Elucirem®(Gadopiclenol) son nouveau produit de contraste pour les examens d’imagerie par résonance magnétique (IRM). Villepinte, le 20 novembre 2024 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce le lancement commercial en France de son nouveau produit de contraste Elucirem®, pour les examens d’im...
Solutions30 successfully completes €120 million debt refinancing
Solutions30 successfully completes €120 million debt refinancing Solutions30, a European leader in rapid-response field services for the telecommunications, energy and IT sectors, today announces that it has successfully closed a €120 million credit facility. This new facility, arranged with a syndicate of eight core relationship banks, will refinance the Group’s existing bank debt and provide additional financial means for its continued expansion, notably in the Energy sector. Amaury Boilot, Group General Secretary, commented: "In today’s challenging financing environment, securing the fu...
Solutions30 réalise avec succès le refinancement de sa dette pour 120 ...
Solutions30 réalise avec succès le refinancement de sa dette pour 120 millions d’euros Solutions30, leader européen des services de terrain à intervention rapide pour les secteurs des télécommunications, de l’énergie et de l’informatique, annonce avoir finalisé avec succès un nouveau financement bancaire de 120 millions d’euros. Ce crédit, arrangé avec un syndicat de huit banques partenaires de longue date, permettra de refinancer la dette bancaire existante du Groupe et lui offrira des moyens financiers supplémentaires pour poursuivre son expansion, notamment dans le secteur de l’énergie. ...
SMA Solar Technology AG: 1 director
A director at SMA Solar Technology AG bought 19,200 shares at 11.828EUR and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Amira Manai
- Jerôme Bodin
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
APAML APERAM SA
EVT EVOTEC SE
GBF BILFINGER SE
SCR SCOR SE
BLC BASTIDE LE CONFORT MEDICAL SA
PSM PROSIEBENSAT.1 MEDIA SE
BRBY BURBERRY GROUP PLC
ENI ENI S.P.A.
MBB MBB INDUSTRIES SE
XIOR XIOR STUDENT HOUSING N.V.
REP REPSOL SA
ERG ERG S.P.A.
CARM CARMILA SAS
LTA ALTAMIR ACT PORTEUR
RENE REDES ENERGETICAS NACIONAIS SA
COL INMOBILIARIA COLONIAL SOCIMI SA
BP. BP P.L.C.
DMP DERMAPHARM HOLDING SE
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
S92 SMA SOLAR TECHNOLOGY AG
VK VALLOUREC SA
NA9 NAGARRO
AERO MONTANA AEROSPACE AG
MRX MISTER SPEX SE
NVM NOVEM GROUP SA
SHEL SHELL PLC
CO CASINO GUICHARD-PERRACHON
- Amira Manai
- Jerôme Bodin
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
APAML APERAM SA
EVT EVOTEC SE
GBF BILFINGER SE
SCR SCOR SE
BLC BASTIDE LE CONFORT MEDICAL SA
PSM PROSIEBENSAT.1 MEDIA SE
BRBY BURBERRY GROUP PLC
ENI ENI S.P.A.
MBB MBB INDUSTRIES SE
XIOR XIOR STUDENT HOUSING N.V.
REP REPSOL SA
ERG ERG S.P.A.
CARM CARMILA SAS
LTA ALTAMIR ACT PORTEUR
RENE REDES ENERGETICAS NACIONAIS SA
COL INMOBILIARIA COLONIAL SOCIMI SA
BP. BP P.L.C.
DMP DERMAPHARM HOLDING SE
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
S92 SMA SOLAR TECHNOLOGY AG
VK VALLOUREC SA
NA9 NAGARRO
AERO MONTANA AEROSPACE AG
MRX MISTER SPEX SE
NVM NOVEM GROUP SA
SHEL SHELL PLC
CO CASINO GUICHARD-PERRACHON
- Anis Zgaya
- Louis Boujard
- CFA
SMA Solar Technology AG : The restructuring plan is necessary but not ...
>Integration of the restructuring plan in 2024, and estimates almost unchanged in 2025 and 2026 - We factored the cost of the restructuring plan into our estimates for 2024. We now expect revenues of € 1,489m, down 5.3% on our previous estimates (versus new guidance for between € 1,450m and € 1,500m), EBITDA of -€ 16.4m versus € 108m previously (guidance between -€ 20m and € 20m), EBIT of -€ 85m (guidance between -€ 100m and -€ 50m) and an attributable net result of ...
- Anis Zgaya
- Louis Boujard
- CFA
SMA Solar Technology AG : Le plan de restructuration est nécessaire ma...
>Intégration du plan de restructuration en 2024, et estimations presque inchangées en 2025 et 2026 - Nous avons intégré le cout du plan de restructuration dans nos estimations 2024. Nous attendons désormais un CA de 1489 M€ en baisse de 5.3% par rapport à nos précédentes estimations (contre une nouvelle guidance entre 1450 M€ et 1500 M€), un EBITDA de -16.4 M€ contre 108 M€ précédemment (guidance entre -20 et 20 M€), un EBIT de -85 M€ (guidance entre -100 M€ et -50 M€...
- Thijs Berkelder
- Usama Tariq
ODDO BHF Small & MIDCAP MORNING NEWS - Date1
We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...
PBB DEUTSCHE PFANDBRIEFBANK AG
GBF BILFINGER SE
GYC GRAND CITY PROPERTIES SA
ITP INTERPARFUMS
SDF K+S AG
NEX NEXANS SA
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
ADN1 ADESSO AG
GNFT GENFIT SA
PAT PATRIZIA AG
SAX STROEER SE & CO. KGAA
NVG NAVIGATOR COMPANY SA
ASS APPLUS SERVICES S.A.
S92 SMA SOLAR TECHNOLOGY AG
CLA CLARANOVA SE
SRAIL STADLER RAIL AG
KTA KNAUS TABBERT
UPG UNIFIEDPOST GROUP
DEME DEME GROUP NV
AF AIR FRANCE - KLM
- Thijs Berkelder
- Usama Tariq
ODDO BHF Small & MIDCAP MORNING NEWS - 11/14/2024
We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...
PBB DEUTSCHE PFANDBRIEFBANK AG
GBF BILFINGER SE
GYC GRAND CITY PROPERTIES SA
ITP INTERPARFUMS
SDF K+S AG
NEX NEXANS SA
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
ADN1 ADESSO AG
GNFT GENFIT SA
PAT PATRIZIA AG
SAX STROEER SE & CO. KGAA
NVG NAVIGATOR COMPANY SA
ASS APPLUS SERVICES S.A.
JST JOST WERKE AG
S92 SMA SOLAR TECHNOLOGY AG
CLA CLARANOVA SE
SRAIL STADLER RAIL AG
KTA KNAUS TABBERT
UPG UNIFIEDPOST GROUP
DEME DEME GROUP NV
AF AIR FRANCE - KLM
- Anis Zgaya
- Louis Boujard
- CFA
SMA Solar Technology AG : Q3 2024 weak as expected and full-year guida...
>Weak Q3 as expected impacted by persistent weakness of Home Solutions and C&I segments and by a slightly less robust quarter in Large Scale - SMA’s reported Q3 2024 results were weak as expected. Sales came in at € 300m, down 46% vs Q3 2023, below consensus expectations at € 330m. EBITDA was € 3m (-97% y-o-y) above the company-compiled consensus of € 0m and bang in line with our forecast of € 3m. The Q3 EBITDA margin thus came to 0.97%, above the consensus forecast o...
- Anis Zgaya
- Louis Boujard
- CFA
SMA Solar Technology AG : Q3 2024 weak as expected and full-year guida...
>Weak Q3 as expected impacted by persistent weakness of Home Solutions and C&I segments and by a slightly less robust quarter in Large Scale - SMA’s reported Q3 2024 results were weak as expected. Sales came in at € 300m, down 46% vs Q3 2023, below consensus expectations at € 330m. EBITDA was € 3m (-97% y-o-y) above the company-compiled consensus of € 0m and bang in line with our forecast of € 3m. The Q3 EBITDA margin thus came to 0.97%, above the consensus forecast o...
EQS-News: SMA publishes figures for the first nine months of 2024, red...
EQS-News: SMA Solar Technology AG / Key word(s): Quarterly / Interim Statement/Restructure of Company SMA publishes figures for the first nine months of 2024, reduces its sales and earnings guidance and sets out details of restructuring and transformation program 14.11.2024 / 00:02 CET/CEST The issuer is solely responsible for the content of this announcement. SMA publishes figures for the first nine months of 2024, reduces its sales and earnings guidance and sets out details of restructuring and transformation program Sales for the first nine months come in at €1,059...
EQS-News: SMA veröffentlicht Neunmonatszahlen 2024, reduziert die Umsa...
EQS-News: SMA Solar Technology AG / Schlagwort(e): Quartals-/Zwischenmitteilung/Unternehmensrestrukturierung SMA veröffentlicht Neunmonatszahlen 2024, reduziert die Umsatz- und Ergebnisprognose und gibt Details zum Restrukturierungs- und Transformationsprogramm bekannt 14.11.2024 / 00:02 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. SMA veröffentlicht Neunmonatszahlen 2024, reduziert die Umsatz- und Ergebnisprognose und gibt Details zum Restrukturierungs- und Transformationsprogramm bekannt Umsatz nach neun Monaten bei 1.059,...
GUERBET : Nombre d'actions et de droits de vote composant le capital d...
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 octobre 2024 GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 octobre 2024 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, les sociétés dont des actions sont admises aux négociations sur un marché réglementé publient sur leur site Internet et transmettent à l'AMF, à la fin de chaque mois, le nombre total de droits de vote et le nombre d'actions composant le capital de la société ...
OSE Immunotherapeutics: 2 directors
Two Directors at OSE Immunotherapeutics sold 40,000 shares at between 9.988EUR and 10.009EUR. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.